ROS1 alterations as a potential driver of gliomas in infant, pediatric, and adult patients.

[1]  D. Brat,et al.  Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. , 2022, Archives of pathology & laboratory medicine.

[2]  M. Caulo,et al.  Molecular Landscape in Infant High-Grade Gliomas: A Single Center Experience , 2022, Diagnostics.

[3]  David C. Jones,et al.  GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types , 2021, Acta Neuropathologica.

[4]  M. Tsao,et al.  Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer—A Cost-Efficient Strategy in a Public Healthcare System , 2021, Current oncology.

[5]  Sandeep Kumar Dhanda,et al.  Lorlatinib in a Child with ALK-Fusion-Positive High-Grade Glioma. , 2021, The New England journal of medicine.

[6]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[7]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  Mariella G. Filbin,et al.  Molecular and clinicopathologic features of gliomas harboring NTRK fusions , 2020, Acta Neuropathologica Communications.

[9]  Marilyn M. Li,et al.  Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. , 2020, Cancer cell.

[10]  Marilyn M. Li,et al.  Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors. , 2020, Cancer genetics.

[11]  Duna H. Barakeh,et al.  Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia , 2020, PloS one.

[12]  B. Orr,et al.  Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case. , 2020, Journal of pediatric hematology/oncology.

[13]  K. Davies,et al.  Targetable molecular alterations in congenital glioblastoma , 2019, Journal of Neuro-Oncology.

[14]  M. Snuderl,et al.  GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors. , 2019, Journal of neuropathology and experimental neurology.

[15]  Arun K. Ramani,et al.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.

[16]  M. Varella‐Garcia,et al.  Clinical and Molecular Characterization of Adult Glioblastomas in Southern Brazil , 2019, Journal of neuropathology and experimental neurology.

[17]  T. Kohno,et al.  Identification of a novel KLC1–ROS1 fusion in a case of pediatric low-grade localized glioma , 2018, Brain Tumor Pathology.

[18]  Erwin G. Van Meir,et al.  Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma , 2018, Clinical Cancer Research.

[19]  David T. W. Jones,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[20]  A. Shaw,et al.  Recent Advances in Targeting ROS1 in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[22]  James Suh,et al.  Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures , 2017, The oncologist.

[23]  Lina Shao,et al.  Clinical Application of Whole Genome Array Improves the Diagnosis of Pediatric Brain Tumors , 2017, International journal of surgical pathology.

[24]  R. Roskoski.  ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. , 2017, Pharmacological research.

[25]  J. Biegel,et al.  Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor. , 2017, Journal of neurosurgery. Pediatrics.

[26]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[27]  S. Bens,et al.  Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3) , 2016, Genes, chromosomes & cancer.

[28]  N. Banik,et al.  Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma , 2015, Cancer growth and metastasis.

[29]  T. Venesio,et al.  Screening for the FIG‐ROS1 fusion in biliary tract carcinomas by nested PCR , 2014, Genes, chromosomes & cancer.

[30]  Wei Huang,et al.  Downregulation of ROS-FIG inhibits cell proliferation, colony-formation, cell cycle progression, migration and invasion, while inducing apoptosis in intrahepatic cholangiocarcinoma cells , 2014, International journal of molecular medicine.

[31]  Y. Totoki,et al.  Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.

[32]  R. Doebele,et al.  Molecular Pathways Molecular Pathways : ROS 1 Fusion Proteins in Cancer , 2013 .

[33]  T. Gu,et al.  Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.

[34]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Greenwood,et al.  Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours , 2011, PloS one.

[36]  Keara M. Lane,et al.  Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. , 2009, Cancer research.

[37]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[38]  Keara M. Lane,et al.  Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) , 2003, Genes, chromosomes & cancer.

[39]  T. Cheng.  Re: Nocturnal diaphoresis and coronary artery spasm. , 1988, Cleveland Clinic journal of medicine.

[40]  M. Wigler,et al.  Expression and rearrangement of the ROS1 gene in human glioblastoma cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Epand,et al.  The existence of a highly ordered phase in fully hydrated dilauroylphosphatidylethanolamine. , 1983, Biochimica et biophysica acta.

[42]  OUP accepted manuscript , 2022, Neuro-Oncology.

[43]  T. O. Bontell,et al.  Novel TPR::ROS1 Fusion Gene Activates MAPK, PI3K and JAK/STAT Signaling in an Infant-type Pediatric Glioma , 2022, Cancer Genomics & Proteomics.